EDESA BIOTECH, INC. Accounts Payable and Accrued Liabilities, Noncurrent
EDESA BIOTECH, INC. (EDSA) had Accounts Payable and Accrued Liabilities, Noncurrent of $0 as of 2023-06-30, per its 10-Q filed 2023-08-09.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent · last filed 2023-08-09
- 2023-06-30: Accounts Payable and Accrued Liabilities, Noncurrent $0.00.
- 2023-03-31: Accounts Payable and Accrued Liabilities, Noncurrent $44.34K.
- 2022-12-31: Accounts Payable and Accrued Liabilities, Noncurrent $44.28K.
- 2022-09-30: Accounts Payable and Accrued Liabilities, Noncurrent $43.66K.
| Period end | Accounts Payable and Accrued Liabilities, Noncurrent |
|---|---|
| 2023-06-30 | $0.00 10-Q · filed 2023-08-09 |
| 2023-03-31 | $44.34K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $44.28K 10-Q · filed 2023-02-10 |
| 2022-09-30 | $43.66K 10-Q · filed 2023-08-09 |
| 2022-06-30 | $46.54K 10-Q · filed 2022-08-12 |
| 2022-03-31 | $47.97K 10-Q · filed 2022-05-13 |
| 2021-12-31 | $47.24K 10-Q · filed 2022-02-14 |
| 2021-09-30 | $47.20K 10-Q · filed 2022-08-12 |
| 2021-06-30 | $48.40K 10-Q · filed 2021-08-13 |
| 2021-03-31 | $47.65K 10-Q · filed 2021-05-14 |
| 2020-12-31 | $47.08K 10-Q · filed 2021-02-16 |
| 2020-09-30 | $29.93K 10-K · filed 2021-12-28 |
| 2020-06-30 | $29.32K 10-Q · filed 2020-08-12 |
| 2019-09-30 | $0.00 10-K · filed 2020-12-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B |